Oncolytics Biotech
ONCY
44 hedge funds and large institutions have $6.95M invested in Oncolytics Biotech in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
33% more funds holding
Funds holding: 33 → 44 (+11)
1.58% less ownership
Funds ownership: 8.59% → 7.01% (-1.6%)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
49% less capital invested
Capital invested by funds: $13.6M → $6.95M (-$6.62M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$264K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$178K |
| 3 |
ARC
Advisor Resource Council
Dallas,
Texas
|
+$156K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$86.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$2.33M |
| 2 |
Millennium Management
New York
|
-$133K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$73K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$48.8K |
| 5 |
Squarepoint
New York
|
-$25.6K |
ONCY Hedge Fund Activity: Q4 2023 in Review
44 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2023, worth a combined $6.95M — down 49% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ONCY positions and 5 closed out — a net gain of 11 holders — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $264K. The largest seller was Anson Funds Management, cutting an estimated $2.33M.
- 44 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2023, up from 33 in Q3 2023.
- Funds reported $6.95M of Oncolytics Biotech stock for Q4 2023, down 49% quarter-over-quarter.
- 16 funds opened new Oncolytics Biotech positions in Q4 2023 and 5 closed out, a net change of +11 holders.
- The largest Oncolytics Biotech buyer in Q4 2023 was Morgan Stanley, an estimated $264K added.
- The largest Oncolytics Biotech seller in Q4 2023 was Anson Funds Management, an estimated $2.33M sold.
Based on aggregated 13F filings for Q4 2023.